Immix Biopharma Investor Presentation Deck
NXC-201 - First CAR-T in AL Amyloidosis, a $6 billion market by 2025
Johnson & Johnson
DARZALEX
(daratumumab)
22%
in a sus fue
00 mm 400 mg/20 m
55%
Investigator's
Choice
NM
response rates in relapsed/refractory AL Amyloidosis
NXC-201
Best Hematologic
Response and
I Cardiac Response
NM
AstraZeneca
CAELUM
BIOSCIENCES
CAEL-101
100%
Hematologic Overall Response Rate
prothena
Birtamimab
-
39%
NXC-201
35%
1 63% 1
Median Reduction from baseline NT-proBNP
●
●●●
IMMIX
S BIOPHARMA
NXC-201 Only CAR-T in AL
Amyloidosis
NXC-201 100% Overall
Response Rate in
relapsed/refractory AL
amyloidosis (median 6 lines of
therapy prior to NXC-201 - all
including Darzalex)
Cardiac Response exceeds
purpose-designed CAEL-101 and
Birtamimab for relapsed/
refractory patients
Zero Neurotoxicity of any grade
in AL Amyloidosis
Birtamimab Source: Gertz MA et al. J Clin Oncol. 2016; CAEL-101 source: Edwards CV, et al. Blood. 2021 Darzalex source: Theodorakakou, et al, 2022 - Outcomes of Patients with AL Amyloidosis after Failure of Daratumumab-Based Therapy - Blood (2022) 140 (Supplement 1): 4275-4276 https://doi.org/10.1182/blood-2022-165403., Point-of-care CART
manufacture and delivery: Expanding access to CART therapy via local institutions, Hadassah Medical Center experience. Poster Presentation, European Society for Blood and Marrow Transplantation and European Hematology Association 5th European CAR T-cell Meeting. 2023 Feb 9-11. Assayag, M, et al. Stepensky. Point-of-care CART manufacture and
delivery for the treatment of multiple myeloma and AL amyloidosis: the experience of Hadassah Medical Center. Poster Presentation, European Society for Blood and Marrow Transplantation 49th Annual Meeting, 2023 Apr 23-26. Asherie N. et al, Oral Presentation. ASGCT, 2023.The Amyloidosis market was $3.6 billion in 2017, expected to reach $6 billion in
2025, according to Grand View Research. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies.. Figures reflect cross-trial comparison and not results from a head-to head study. Differences exist between trial designs and subject characteristics, and caution should be
exercised when comparing data across studies. Lebel, E., et al. Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis. American Society of Hematology 65th Annual Meeting, 2023.
22View entire presentation